Fractyl Health’s Post

The incorporation of choline into PLGA-PEG copolymers can provide additional advantages.Choline possesses a positive charge,which can promote interactions with negatively charged cell membranes,facilitating cellular uptake and enhancing the efficacy of drug delivery.PLGA-PEG-choline copolymers have been studied for applications such as targeted drug delivery and gene therapy.The positive charge of the choline moiety makes it suitable for targeted drug delivery to specific cells or tissues.  #choline #PLGA #PEG #cells #tissues #copolymers #drug https://lnkd.in/ge3r2CTy

Plasmids, used to deliver gene therapies, must be free of contaminating proteins that may cause adverse side effects. UV-Vis spectrophotometry is a fast and simple technique that can be easily implemented at several points in the plasmid manufacturing workflow to help ensure consistency and to maintain safety and efficacy. Learn how. https://lnkd.in/gfisHJa6 #TFSCAD

𝐁𝐫𝐢𝐧𝐠𝐢𝐧𝐠 𝐍𝐞𝐰 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭𝐬 𝐭𝐨 𝐏𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐰𝐢𝐭𝐡 𝐑𝐚𝐫𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞𝐬: 𝐃𝐞𝐬𝐢𝐠𝐧𝐢𝐧𝐠 𝐚𝐧𝐝 𝐂𝐨𝐧𝐝𝐮𝐜𝐭𝐢𝐧𝐠 𝐄𝐟𝐟𝐞𝐜𝐭𝐢𝐯𝐞 𝐆𝐞𝐧𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐓𝐫𝐢𝐚𝐥𝐬 Gene therapy trials face unique challenges that go beyond traditional drug testing. Operational, regulatory, and biosafety considerations are critical for success. Chris Doyle, latest book delves into these complexities, providing invaluable insights for trial sponsors. Learn how to navigate these trials smoothly and safely to bring new hope to patients with rare diseases. 🔗 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫 𝐦𝐨𝐫𝐞: https://lnkd.in/g9YE6ZbR 👉𝐕𝐢𝐬𝐢𝐭 𝐨𝐮𝐫 𝐰𝐞𝐛𝐬𝐢𝐭𝐞: https://lnkd.in/dd4w2vnF 🔗 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐭𝐡𝐞 𝐞-𝐛𝐨𝐨𝐤 𝐧𝐨𝐰: https://lnkd.in/gv7R4SPi #GeneTherapy #ClinicalTrials #RareDiseases #InnovativeMedicine #RegulatoryCompliance #Biosafety #MedicalResearch #HealthcareInnovation #GeneTherapyTrials #ClinicalResearch #NewTreatments #MedicalTrials #PatientCare #TherapeuticDevelopment #Biotech

Trying to balance life-changing gene therapies and their steep costs? Watch this recording of our latest SHRM webinar from Aetna, a CVS Health Company for insights on the benefits and financial risks of these breakthrough therapies and their impact on the bottom line. #CECredit #SHRM Alberto Santos, Rahul R., Jeanne McKinney

💰 Rising Healthcare Costs in 2024 💰 Healthcare costs are on the rise, with $2 million+ claims becoming more frequent. Gene therapy approvals are soaring, with 14 new GTs on the market in mid-2024. Stay informed about how these trends might impact your plan sponsors. #HealthcareCosts #GeneTherapy #InsuranceTrends #Virtuehealth #virtuehealthconsortium

🔬🌐 The European Medicines Agency endorses WFH's Gene Therapy Registry! 🌟 This initiative, in collaboration with esteemed partners, is a game-changer for the Hemophilia community. 📊 The GTR's global reach is a beacon of hope, consolidating invaluable data on Hemophilia gene therapy patients worldwide. This approach not only eliminates redundancy but also promises to uncover rare safety events and elevate the overall quality of care. 💪 The primary goal of long-term safety assessment is paramount, shedding light on known and unforeseen issues. Moreover, the GTR's emphasis on efficacy and durability ensures a holistic view of Hemophilia gene therapy's impact. 🌈 It's heartening to see the commitment to patient-centric care, with programs to empower both #healthcare centers and #patients in data management. Privacy compliance is a top priority, reassuring all stakeholders. 🤝 The collaborative governance structure, complete with a Patient Advisory Group, sets a gold standard for transparent, patient-driven research. 🧬 As we embrace the future of Hemophilia care, the GTR promises to be a vital tool in shaping regulatory decisions, health technology assessments, and clinical practice #guidelines. 🚀 Looking forward to witnessing the transformative impact of the WFH GTR and its role in advancing gene therapies for Hemophilia. #Hemophilia #GeneTherapy #PatientCare #DataForChange #HealthcareInnovation https://lnkd.in/ddGJHpcg

During a presentation at the annual meeting of the European Association for the Study of Diabetes e.V. (EASD), Fractyl Health unveiled compelling findings regarding its GLP-1-based pancreatic gene therapy, commercially known as Rejuva. The data showcased a remarkable performance in weight loss, particularly when compared to semaglutide injections, at least in the context of experiments conducted with mice. #DiabetesResearch 🩺#EASDConference 🌐#PancreaticGeneTherapy 🔬#FractylHealth 💪#GLP1Therapy 🧬#Rejuva 🌟#WeightLossResults 🏋️♂️#SemaglutideComparison 📊#MedicalBreakthroughs 🚀#HealthInnovation 💡#ClinicalFindings 📈#MouseExperiments 🐁#MedicalResearchUpdate 📚#DiabetesManagement 🌡️#InnovativeTherapies 💉

Peruse the news from our current issue, including FDA approvals, gene therapy trial updates, J code news, and more: https://lnkd.in/e6CDDErh #ophthalmology #genetherapy #retinaldisease #clinicaltrials

Now Open: The 2024 USI Benefits Benchmarking Study is now open through April 4. See how your benefit plans compare to industry peers and learn steps you can take to optimize your offerings, so your employees feel like they’ve made the best choice for themselves and their families. – join 10,000+ employers in the largest survey of its kind. New questions in the 2024 survey examine how employers are addressing several high-cost challenges such as: -New and emerging gene therapies -Diabetic GLP-1 medications used for weight loss -Population health management Participating organizations will receive a complementary, customized plan performance assessment in late May. Click to get started: https://lnkd.in/g6rMraEY

Vehicles: "A noncationic lipid nanoparticle was constructed for mRNA delivery with simple, convenient, and repeatable preparation technology, negligible inflammatory and cytotoxicity side effects, high gene transfection efficiency, and spleen-targeting delivery to induce immunity for disease treatments" https://lnkd.in/d7BUFqmm